List view / Grid view
Optimisation of a hit towards a lead happens in a variety of ways, as a lead needs to meet various criteria such as activity, affinity to the target, selectivity, solubility, permeability or metabolic stability to become a promising candidate. A balance between in vitro profiles and pharmacokinetic attributes has to…
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.